Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Novartis Pharma AG
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies
Dose escalation phase Primary objective: 1.To determine the maximum tolerated dose (MTD) or the recommended Phase II dose of HCD122 when administered as a single agent intravenously (IV) once weekly f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Safety and efficacy of secukinumab compared to placebo in patients with active rheumatoid arthritis who did not respond to anti-TNFα drugs
Demonstrate the efficacy of secukinumab (75mg or 150mg) versus placebo (measured with ACR 20) after 24 weeks of treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with mild Alzheimer’s disease (AD) or Mild Cognitive Impairment (amnestic MCI)
To assess AQW051 as a cognitive enhancer, as measured by selected tests (PAL, SWM, RVP) from the CANTAB computerized cognitive test battery, in patients with findings consistent with mild Alzheimer’s ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, CellCept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipients
The purpose of this two-year extension is to allow patients who have completed the one-year core study to continue treatment with FTY720 or MMF in combination with reduced or full-dose Neoral (per ran...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG (UK)
MAJ Il y a 5 ans
Evaluation of an electronic Oral Glucose Tolerance Test Kit (eOGTTK)
Background and study aims In routine clinical practice, the most accurate way to diagnose diabetes is by conducting an Oral Glucose Tolerance Test (OGTT). An OGTT is conducted in a clinical setting (h...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
Efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis over 12 weeks based on PASI and IGA
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A 52-week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar I disorder
To assess the tolerability and safety of open-label treatment with licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6 week double- blind study CLIC477D2302, with respect to the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A community setting study of malaria after systematic treatment of symptomatic carriers of P. Falciparum with COA566 (Coartem®)
• To evaluate at the community level whether treatment of AC of P falciparum is associated with a lower number of symptomatic malaria episodes RDT confirmed (SMRCs) per person-year over a 12 month fo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Efficacy and safety study of 4 doses of QGE031 in patients 18-50 years of age with peanut allergy
The increase in the threshold dose of peanut protein that induces objective hypersensitivity reactions after treatment assessed by double-blind, placebo-controlled oral food challenges (DBPCFC) before...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis
To evaluate the long-term efficacy of secukinumab with respect to ACR20, ACR50 and ACR70 response over time up to Month 60 in patients who completed the phase III study CAIN457F2309
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant